NASDAQ: PALI
Palisade Bio Inc Stock

$0.81+0.05 (+6.58%)
Updated May 23, 2025
PALI Price
$0.81
Fair Value Price
$1.13
Market Cap
$3.87M
52 Week Low
$0.60
52 Week High
$5.15
P/E
-0.12x
P/B
0.73x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.14M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.54
Operating Cash Flow
-$11M
Beta
1.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

PALI Overview

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine PALI's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
PALI
Ranked
Unranked of 455

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$45.93A
$8.08A
$42.39A
View Top Biotech Stocks

Be the first to know about important PALI news, forecast changes, insider trades & much more!

PALI News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PALI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PALI ($0.81) is undervalued by 28.6% relative to our estimate of its Fair Value price of $1.13 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PALI ($0.81) is significantly undervalued by 28.6% relative to our estimate of its Fair Value price of $1.13 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PALI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PALI due diligence checks available for Premium users.

Valuation

PALI fair value

Fair Value of PALI stock based on Discounted Cash Flow (DCF)

Price
$0.81
Fair Value
$1.13
Undervalued by
28.33%
PALI ($0.81) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PALI ($0.81) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PALI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PALI price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.12x
Industry
-176.38x
Market
21.18x

PALI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.73x
Industry
4.29x
PALI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PALI's financial health

Profit margin

Revenue
$0.0
Net Income
-$2.2M
Profit Margin
0%
PALI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$8.2M
Liabilities
$2.9M
Debt to equity
0.54
PALI's short-term assets ($7.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PALI's short-term assets ($7.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PALI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PALI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.3M
Investing
$0.0
Financing
-$258.0k
PALI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PALI vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
PALI$3.87M+6.75%-0.12x0.73x
GLTO$3.95M+0.95%-0.19x0.29x
TTNP$3.99M-4.90%-0.95x2.13x
TOVX$3.73M-1.94%-0.03x0.24x
ADTXD$3.69M-4.40%0.00x0.22x

Palisade Bio Stock FAQ

What is Palisade Bio's quote symbol?

(NASDAQ: PALI) Palisade Bio trades on the NASDAQ under the ticker symbol PALI. Palisade Bio stock quotes can also be displayed as NASDAQ: PALI.

If you're new to stock investing, here's how to buy Palisade Bio stock.

What is the 52 week high and low for Palisade Bio (NASDAQ: PALI)?

(NASDAQ: PALI) Palisade Bio's 52-week high was $5.15, and its 52-week low was $0.60. It is currently -84.33% from its 52-week high and 34.5% from its 52-week low.

How much is Palisade Bio stock worth today?

(NASDAQ: PALI) Palisade Bio currently has 4,795,646 outstanding shares. With Palisade Bio stock trading at $0.81 per share, the total value of Palisade Bio stock (market capitalization) is $3.87M.

Palisade Bio stock was originally listed at a price of $3,743,999.25 in Mar 30, 2007. If you had invested in Palisade Bio stock at $3,743,999.25, your return over the last 18 years would have been -100%, for an annualized return of -57.38% (not including any dividends or dividend reinvestments).

How much is Palisade Bio's stock price per share?

(NASDAQ: PALI) Palisade Bio stock price per share is $0.81 today (as of May 23, 2025).

What is Palisade Bio's Market Cap?

(NASDAQ: PALI) Palisade Bio's market cap is $3.87M, as of May 24, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Palisade Bio's market cap is calculated by multiplying PALI's current stock price of $0.81 by PALI's total outstanding shares of 4,795,646.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.